← Issue №17/ week of Oct 25, 2026/IBD

Meta-Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD meta analysis · n=394 · Oct 21, 2026 · Aliment Pharm Ther · IF 6.7

Meta-Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis.

New evidencePSCbiologicsJAK inhibitorsmeta-analysis
Clinical takeawayConsider advanced therapies (e.g., infliximab, adalimumab, vedolizumab, tofacitinib) for PSC-IBD patients, acknowledging modest remission rates (24.7% at 3 months, 28.6% at 6-12 months) and acceptable safety, but remain cautious due to limited evidence from retrospective studies and a 9.1% adverse event-related discontinuation rate.
What it foundPooled clinical remission rates in PSC-IBD were 24.7% at 3 months and 28.6% at 6-12 months with advanced therapies.
ContextConfirms modest effectiveness of advanced therapies in PSC-IBD, a high-risk population with limited prior evidence on IBD-specific outcomes and a 10.5% pooled colorectal neoplasia risk.
Emergingsuggested applicable standard· AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline

Decision at stakethe use of advanced therapies in PSC-IBD patients

… For colorectal surveillance, begin surveillance colonoscopy at the time of PSC-IBD diagnosis (or at age 15 for childhood-onset disease) and repeat at 1-2 year intervals; in PSC without IBD, perform a diagnostic colonoscopy at PSC diagnosis and repeat every 5 years if IBD is not found. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. No disease-modifying therapy is proven to alter transplant-free survival, but moderate-dose UDCA (13-23 mg/kg/day) may now be considered and continued in patients not enrolled in or eligible for a clinical trial if it produces a meaningful improvement in alkaline phosphatase (GGT in children) and/or symptoms by 12 months, discontinuing if no response; high-dose UDCA remains contraindicated. Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). Manage gallbladder polyps by size, cholecystectomy for polyps >8 mm, ultrasound surveillance every 6 months for polyps ≤8 mm, rather than referring every polyp. For colorectal surveillance, begin surveillance colonoscopy at the time of PSC-IBD diagnosis (or at age 15 for childhood-onset disease) and repeat at 1-2 year intervals; in PSC without IBD, perform a diagnostic colonoscopy at PSC diagnosis and repeat every 5 years if IBD is not found. Evaluate dominant strictures with brush cytology plus FISH (± cholangioscopy) before/at balloon dilation, repeating ERCP with sampling in 3 months if cytology is suspicious regardless of FISH result. Treat recurrent cholangitis and cholestatic pruritus, maintain bone health, and refer for transplant evaluation for decompensation, intractable pruritus, recurrent bacterial cholangitis, or early-stage CCA per Mayo protocol.

AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline · reviewed 2026-07-24 ↗
Elzubeir A … Lynch KD · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues